1. Diabetes action Canada annual workshop
Friday, MAY 31, 2019
Does Sodium Linked Transporter (SGLT) Inhibition Improve Performance of the Artificial Pancreas in Type 1 Diabetes?
Bruce A. Perkins, Leif E. Lovblom, Nancy Cardinez, Andrej Orszag,
Marcelo Falappa, Devrim Eldelekli, Daniel Scarr, Ahmad Haidar
Bruce A. Perkins MD MPH
Professor and Clinician-Scientist
Sam and Judy Pencer Family Chair in Diabetes Clinical Research
Leadership Sinai Centre for Diabetes
Division of Endocrinology

2. Does Sodium Linked Transporter (SGLT) Inhibition Improve
Performance of the Artificial Pancreas in Type 1 Diabetes?
Study purpose:
We aimed to determine if Empagliflozin (EMPA) can improve the performance of the artificial pancreas and reduce carbohydrate counting burden from patients.
Current artificial pancreas algorithms regulate blood sugars during the night time but not very well following meals
Sodium Glucose-Linked Transporter inhibitors (SGLTi) like EMPA lower blood glucose through elimination of sugar in the urine and may help the artificial pancreas algorithm work better with meals
Artificial Pancreas (AP)
Trial Design:
We are currently doing a randomized placebo-controlled trial of EMPA in people living with T1D using the McGill Artificial Pancreas algorithm, and we have preliminary results on 16 people

3. Does Sodium Linked Transporter (SGLT) Inhibition Improve
Performance of the Artificial Pancreas in Type 1 Diabetes?
TIR= Time in Range ( mmol/l
Preliminary results suggest that SGLT inhibition added to the Artificial Pancreas substantially improved glucose control, can reduce patients’ need for burdensome carbohydrate counting and appears safe.